secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-036278
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell narrows Q4 net loss to $3.3M; OpRegen gets FDA RMAT designation
----------------------------------------------------------------------------

- Net loss of $3.3M ($0.02/shr) for Q4 2024 vs $4.8M ($0.03/shr) in Q4 2023; revenue $2.9M vs $2.1M.
- Cash of $47.8M at Dec 31, 2024 plus $5.5M from Jan 2025 close; funds operations into Q1 2027.
- OpRegen (dry AMD/GA) received FDA RMAT designation; positive 24-month visual acuity data reported.
- OPC1 DOSED study initiated Feb 2025 in spinal cord injury; UC San Diego Health first site.
- Closed financings for $44M gross proceeds; potential $36M from milestone-linked warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025036278/0000950170-25-036278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025036278/lctx-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer